List of Biologics Companies in Singapore - 16

Albatroz Therapeutics is a pre-clinical stage biotech company developing therapeutic antibodies and ADCs to treat solid tumours and arthritis, based on its proprietary position over a novel target critical to ECM degradation.

Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.

Biosyngen is a cell therapy company focusing on unmet needs with technology targeting solid tumors and lymphoproliferative diseases. The company’s first-in-class products have entered into Phase I/II clinical trials for nasopharyngeal cancer (ODD and Fast-Track), lymphoproliferative disease and lung cancer. The company continues to enrich its pipeline with further IND submissions. Biosyngen drives its global strategy from the dual HQ in Singapore and Guangzhou. Leverages on the public-private biopharma ecosystem for the better cause. Committed to giving cancer patients a better chance to survive, our pipeline is enriched, covering other major indications which are on track for regulatory registration. Biosyngen seeks breakthrough in collaborations, particularly in translational R&D and clinical development. The company has positioned GMP cell therapy manufacturing facilities in two locations - in Singapore and Guangzhou covering global needs. To quicken drug development from bench-to-bedside, a parallel effort in the form of the Translational Medicine Centre is set up. It is public-private-partnership connecting stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises and Venture Capital.

CellResearch Corporation was founded in Singapore in 2002 by scientists with a keen interest and expertise in Cell Biology. In 2004, our scientists isolated Epithelial and Mesenchymal Stem Cells from the Umbilical Cord Lining Membrane. This novel and significant discovery was put up for intellectual property protection, and to date we have patents granted in multiple strategic key territories around the world. The umbilical cord lining membrane is now known to be the richest source of stem cells in the body, and both epithelial and mesenchymal stem cells are being researched intensively with collaborators all around the world to exploit their potential for downstream medical therapy. Considerable headway has already been achieved, and we have started USFDA Clinical Trials with our collaborators in the USA, leading to a therapy to accelerate wound healing.

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors.

DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.

Evive Biotech is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, Singapore, and China. As the first biopharmaceutical company to build a platform bringing innovative therapies from China to the world, Evive adopts a holistic approach to drug development, combining exceptional research and commercialization capabilities with our world-class in-house regulatory expertise and extensive international management experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global market quickly and efficiently to address unmet medical needs, making a real and lasting difference to patients and their families worldwide.

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. Sign up for our updates here: https://bit.ly/HMBDNews

Juniper Biologics is birthed on the basic premise that access to healthcare is a birthright. We are a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients everywhere by building a growing presence in oncology, rare/orphan diseases and gene therapy. Juniper Biologics was founded on a vision to create a pharmaceutical business that is both agile and innovative. This includes a commitment to providing treatments for unmet needs focused on specialist therapy areas in which we can make the most difference. Our purpose is clear: to do all that we can to change the treatment landscape and address the unmet medical needs of patients, and to do it as quickly as possible. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. This is just the beginning of our story… and we are just getting started.

Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.

MediSix Therapeutics - We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery

PairX is pioneering the development of next-generation cancer-selective biologics by identifying novel, highly prevalent, tumor-selective cell surface variants. Our biology-driven approach reveals a new class of therapeutic targets that can be paired with a variety of optimal therapeutic modalities. Founded on IP exclusively licensed from Duke-NUS Medical School, Singapore, PairX is advancing a robust pipeline of potential first- and best-in-class tumor-selective therapies targeting prevalent cancers in substantial patient populations.

Established and headquartered in Singapore, SCG Cell Therapy Pte Ltd (SCG) is a leading biotechnology company that combines regional advantages in Singapore, China and Germany, to cover the entire value chain from innovative drug research and discovery, manufacturing, clinical development and commercialization. SCG specializes in the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers. SCG collaborates with leading scientists and researchers to bring first-in-class medical products/technologies to enhance innovation in medical product development.

SABio is a biotechnology company that offers quality custom-made RNA oligos/siRNAs, peptides, ready-made antibodies, custom antibody production services, and more.